Our Pipeline and Products

Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.

MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.

Share your partnering idea

Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.

 

Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.

Our Values

Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.

 

What does it really make Menarini unique? The diversity and authenticity of our key resource - the People.
Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.

Available positions on Linkedin

Menarini employees make all the difference, every day.

 

Pharmaceuticals

Gout

Diet (red meat, seafood), genetic factors, male gender, increased age ,overweight, menopause, alcohol, myeloproliferative malignancies, renal impairment, dehydration and medicines (diuretics, some hypertensive drugs and anti-neoplastic drugs) are mostly associated to gout.

The clinical progression of gout can be defined by four stages:

  • Asymptomatic hyperuricemia
  • Acute gout or gout flare: characterized by the deposition of crystals intra joint causing inflammation. It is associated to intense pain, redness, heat and swelling at the affected joint and surrounding tissues, such as big toe and elbow. Most frequently the attacks occur during the night waking up the patient. Different factors like food, stress, drugs and alcohol can trigger the attacks. Usually the symptoms disappear in 1–2 weeks. With the progression of the disease, the frequency of the episodes increases as the number of joints involved and the interval between every episodes is every time shorter.
  • Intercritical period: phase between two acute gout episodes without any signs or symptoms. It can be prolonged by avoiding the triggering factors.
  • Chronic gout: it occurs when none therapy has been established, usually after some years from the first acute episode. Its distinctive feature are the thopi, large visible bumps made of urate crystals. If not treated it can lead to joint deformity, osteoarthritis and bone loss, urate nephropathy and ocular complications. It is important to underline that chronic hyperuricemia is a risk factor for cardiovascular disease.

Gout is a treatable disease. The purpose of the therapy is to promote the dissolution of the crystal deposits and getting the blood uric acid level under control in order to reduce the formation of new crystals. Dietary modifications, reduction of alcohol consumption and weight loss are key points for the correct management of gout. In case of acute attacks NSAIDs are usually effective. Your doctors may prescribe your different types of drugs to treat this condition.